WallStreetZenWallStreetZen

NASDAQ: VTGN
Vistagen Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Vistagen Therapeutics earnings were -$47.3M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest VTGN earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$14.1M, up 8.7% from last quarter. For the last reported fiscal year 2024 ending Mar 31, 2024, VTGN reported annual earnings of -$29.4M, with -50.4% growth.

VTGN earnings history

Current Revenue
$698.3k
Current Earnings
-$47.3M
Current Profit Margin
-6,774.2%

VTGN Return on Equity

Current Company
-48.1%
Current Industry
-2%
Current Market
34.1%
VTGN's Return on Equity (-48.1%)... subscribe to Premium to read more.
High Return on Equity Performance

VTGN undefined

Current Company
-43.8%
Current Industry
-0.4%
VTGN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when VTGN announces earnings.

VTGN undefined

Current Company
-57.2%
Current Industry
5.9%
VTGN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

VTGN vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
VTGN-$46.68M-$47.30MN/A-$1.48
IVVD-$166.81M-$169.93MN/A-$1.43
ANRO-$59.22M-$61.43MN/A-$2.50
ADVM-$105.78M-$130.93MN/A-$6.62
ADAP-$52.67M-$70.81MN/A-$0.30
View Top Biotech Stocks

Vistagen Therapeutics Earnings Reports & History FAQ

What were Vistagen Therapeutics's earnings last quarter?

On VTGN's earnings call on Invalid Date, Vistagen Therapeutics (NASDAQ: VTGN) reported Q4 2024 earnings per share (EPS) of -$0.46, up 109.09% year over year. Total VTGN earnings for the quarter were -$14.09 million. In the same quarter last year, Vistagen Therapeutics's earnings per share (EPS) was -$0.22.

If you're new to stock investing, here's how to buy Vistagen Therapeutics stock.

Is Vistagen Therapeutics profitable or losing money?

As of the last Vistagen Therapeutics earnings report, Vistagen Therapeutics is currently losing money. Vistagen Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$47.30 million, a 47.51% increase year over year.

What was VTGN's earnings growth in the past year?

As of Vistagen Therapeutics's earnings date in Invalid Date, Vistagen Therapeutics's earnings has grown year over year. VTGN earnings in the past year totalled -$47.30 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.